Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of ASP8825 in Renal Impairment and Haemodialysis
NCT02629224Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2008
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gabapentin enacarbil in restless legs syndrome (RLS) and postherpetic neuralgia (PHN) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Plasma Concentration (Cmax) up to 72 hours, Area Under the Curve (AUC) up to 72 hours and 10 more. Started Feb 2008; status: completed.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT02629224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02629224.